Cargando…
Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers
Oncolytic viruses hold promise as “self-amplifying” cancer therapies wherein a virally killed cell can produce thousands of new viral “drugs” that can kill more cancer cells. Adenoviruses (Ads) are one family of oncolytic viruses. Most human studies have used human Ad serotype 5 (Ad5). Unfortunately...
Autores principales: | Nguyen, Tien V, Heller, Greg J, Barry, Mary E, Crosby, Catherine M, Turner, Mallory A, Barry, Michael A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758940/ https://www.ncbi.nlm.nih.gov/pubmed/26900598 http://dx.doi.org/10.1038/mto.2015.21 |
Ejemplares similares
-
Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer
por: Nguyen, Tien V, et al.
Publicado: (2018) -
Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5
por: Nguyen, Tien V., et al.
Publicado: (2017) -
Targeting strategies of adenovirus-mediated gene therapy and virotherapy for prostate cancer
por: Cai, Zhonglin, et al.
Publicado: (2017) -
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10
por: Bates, Emily A., et al.
Publicado: (2022) -
The Feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to Administer Oncolytic Adenoviruses
por: Tate, Sophia J., et al.
Publicado: (2021)